Asciminib: the next-generation bullet for first-line treatment of chronic myeloid leukemia
- PMID: 39127034
- DOI: 10.1016/j.medj.2024.07.001
Asciminib: the next-generation bullet for first-line treatment of chronic myeloid leukemia
Abstract
The standard of care for chronic myeloid leukemia (CML) involves tyrosine kinase inhibitors (TKIs), which suppress tyrosine kinase activity of BCR::ABL1. Hochhaus et al. reported that asciminib, a BCR::ABL1 inhibitor specifically targeting the ABL myristoyl pocket, showed superior efficacy and favorable safety compared with TKIs in the phase 3 ASC4FIRST trial in patients with newly diagnosed chronic-phase CML.1.
Copyright © 2024 Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of interests C.Y. received research funding from Bristol Myers Squibb. T.T. received honoraria from Novartis.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous